Pompe Disease Therapeutic Market
In the United States, 1 in 40,000 people have Pompe disease. Total carrier frequency (C.F.) and estimated genetic prevalence (pGP) were observed to be, respectively, 1.3% and 1:23,232. Its prevalence is rising, and the healthcare industry places a high priority on its treatment. Oral medications are predicted to accelerate market expansion. Given that the majority of products are available in capsule and tablet form and that this is a very practical route of administration, the segment is anticipated to accelerate the global Pompe Disease Therapeutic Market. Global drug launches will increase demand for pompe disease treatments and fuel the market's expansion.
